Asianet Newsable on MSN
ABVX stock rockets 28% after Abivax eases drug safety concerns with fresh clinical data
Abivax said the findings strengthen the overall case for obefazimod and reinforce its favorable benefit-risk profile.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results